This story was first published in digitalhealth.net
A new trial suggests that fewer, stronger doses of radiotherapy used to treat cancer patients could save the NHS millions.
The CHHiP trial began in 2002 with funding from Cancer Research UK. It recruited men with localised prostate cancer and aimed to test how the size and number of radiotherapy doses affected survival and side effects.
Three groups were involved, with group one having the standard treatment: a daily dose a 2 Gray over 37 treatments, Monday-Friday, for a total of 74 Gray. Group two had a stronger daily dose of 3 Gray, in 20 treatments for a total of 60 Gray. Group three also had a daily dose of 3 Gray, but had 19 treatments for a total of 57 Gray.
After five years, group one, who received a regular dose, saw 88 per cent of patients free from any cancer, while group three, who had lower overall dose of 57 Gray, saw slightly less effective results at 86 per cent.
However, the treatment of fewer, stronger doses given to group two, was found to be just as effective at keeping cancer at bay when compared to the regular dose, with 88 per cent still free from caner five years later.
Additionally, patients in group two who received the stronger daily doses didn’t experience any additional side effects compared to those who received the regular dose, suggesting that fewer, stronger does of radiotherapy can be just as effective at treating prostate cancer.
Professor David Dearnaley, from The Institute of Cancer Research, London, suggests that moving this kind of treatment could mean reducing the burden on patients, as they will need fewer trips to the hospital and can complete their treatment more quickly.
It also has the potential to save millions for the NHS, as well as free up radiotherapy resources, which could potentially reduce waiting times and allow more time for research.
Dearnaley said: “It’s crystal clear from this, the largest trial ever for localised prostate cancer, that men should be treated with fewer, stronger doses. There’s no arguing with the results.”
This story was first published in digitalhealth.net
UK Building Regulations highlight toxic gas and smoke from layers of paint built up over multiple redecorations as a major cause of permanent ill health or death in a building fire.
Their concern rose with discovery the flame retardant paints most widely used paint along escape routes have been ones which to this day counter-productively use emission of heavy toxic gas to smother flames which rapidly spread along walls if layers of paint delaminate in a fire.
Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients
Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho
Sarah Greenslade, public affairs and communications officer at the British Parking Association looks at some of the problems and innovations in healthcare parking
It’s easy to assume that the comms team is there to handle press enquiries and the occasional social media storm – but the reality is that strategic communications can make a measurable impact across the entire organisation, from operational to financial, when done properly